Unicycive Therapeutics, Inc., a biopharmaceutical company, is facing a class action lawsuit that could have significant implications for its shareholders. The lawsuit alleges that Unicycive misled investors about its readiness to meet the U.S. Food and Drug Administration’s (FDA) manufacturing compliance standards. This legal action, filed on behalf of investors who purchased shares between March 29, 2024, and June 27, 2025, seeks to recover losses incurred due to alleged securities fraud.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The core of the complaint centers on accusations that Unicycive overstated its preparedness and capability to comply with FDA requirements, particularly concerning its new drug application for oxylanthanum carbonate. Investors claim that the company’s public statements were materially false and misleading, painting an overly optimistic picture of its regulatory prospects.
For those who invested in Unicycive during the specified period and suffered financial losses, there is an opportunity to seek recovery. Affected shareholders, even those who still hold their shares, are encouraged to visit the following link to learn more about their rights: https://zlk.com/pslra-1/unicycive-therapeutics-inc-lawsuit-submission-form?wire=18. Participation in the lawsuit comes with no cost or obligation.
The lawsuit is spearheaded by Levi & Korsinsky LLP, a firm renowned for its expertise in securities litigation. With a track record of securing hundreds of millions of dollars for shareholders, Levi & Korsinsky has been recognized as one of the top securities litigation firms in the United States for seven consecutive years.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171